Clinical Trials
Ripe for innovation
The pandemic accelerated the adoption of both technologies and new approaches to the conduct of clinical research. We help ensure the best of those advancements become the new best practices.
The pandemic accelerated the adoption of both technologies and new approaches to the conduct of clinical research. We help ensure the best of those advancements become the new best practices.
In this four-part video series, IQVIA R&D leaders explore clinical development transformation in today’s environment. We explore patient centricity, the use of clinical technologies and connected devices, and the incorporation of AI/ML in drug development. Which levers will be most effective in easing patient burden and simplify trial participation? Watch the video series to learn more!
This report assesses the trends in new drug launches and the overall number of initiated clinical trials. It also profiles the state of R&D funding and the activity of companies of different types. The results of research are compared to the input effort in a Clinical Development Productivity Index. The notable acceleration and adaptability of the innovation ecosystem is examined in terms of several enablers of R&D productivity, including the relationship between shortening trial durations and the ‘white space’ within clinical development timelines that have been reducing for some diseases and increasing for others.
This report explores model changes that allowed for clinical trial efficiencies from the perspective of the CRO and is based on a set of workshops with COVID-19 vaccine clinical delivery teams. Our emphasis is on understanding what was possible because of the drastic operating environment changes and assessing what can be carried forward into the post-pandemic clinical development pipeline of therapies for other illnesses.
Technology advancements are allowing data collection in new and less obtrusive ways to the patient. Combined with decentralized models and advanced patient engagement tools, patient-centric drug development is now a reality.
Assess your protocol against real world evidence using advanced analytics, and reduce the risk of costly amendments.
Leverage a global network of Phase I clinical pharmacology units to build diversity in patient populations and access a range of geographic regions for early clinical development (ECD) programs.
Improve the performance of your clinical trials with the power of the IQVIA CORE.
Identify the best performing sites for your trial in less time with new machine learning and predictive modeling methods.
Predict enrollment more accurately and increase the number of patients per site using data-driven patient recruitment solutions.
Access central labs around the globe through Q² Solutions, a wholly owned subsidiary of IQVIA.